Efficacy and safety of tocilizumab in refractory rheumatoid arthritis: A real life cohort from a single centre

Clinical and Experimental Rheumatology

Volumn 32, Issue 4, 2014, Pages 460-464

  Addimanda, Olga ^a   Possemato, Niccolò ^a   Macchioni, Pierluigi ^a   Salvarani, Carlo ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Biologic agents; Long standing disease; Rheumatoid arthritis; Tocilizumab

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; TOCILIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT INDICATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BIOLOGICAL PRODUCTS; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; STEROIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904873291     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. ASH Z, EMERY P: The role of tocilizumab in the management of rheumatoid arthritis. Expert Opin Biol Ther 2012; 12: 1277-89.
2. SMOLEN JS, BEAULIEU A, RUBBERT-ROTH A et al.; OPTION INNVESTIGATORS: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97.
3. MARTI L, SCHEINBERG M: Anti-interleukin 6: first line in rheumatoid arthritis? Clin Rheumatol 2009; 28: 877-9.
4. EMERY P, KEYSTONE E, TONY HP et al.: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67: 1516-23.
5. KANEKO A: Tocilizumab in rheumatoid arthritis:efficacy, safety and its place in therapy. Ther Adv Chronic Dis 2013; 4: 15-21.
6. NAM JL, WINTHROP KL, vanN VOLLENHOVEN RF et al.: Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010; 69: 976-86.
7. KAWASAKI Y, HASHIMOTO T, OKANO T et al.: Shorter disease duration is important for tocilizumab to achieve Boolean remission. Mod Rheumatol 2013.
8. SMOLEN JS, SCHOELS MM, NISHIMOTO N et al.: Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2013; 72: 482-92.
9. YAZICI Y, CURTIS JR, INCE A et al.: Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis:a one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study). Clin Exp Rheumatol 2013; 31: 358-64.
10. EPIS O, FILIPPUCCI E, Delle SEDIE A, De MATTHAEIS A, BRUSCHI E: Clinical and ultrasound evaluation of the response to tocilizumab treatment in patients with rheumatoid arthritis: a case series. Rheumatol Int 2013 Jan 26 [Epub ahead of print].
11. SUZUKI T, HORIKOSHI M, SUGIHARA M et al.: Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI. Mod Rheumatol 2012; 23: 782-7.
12. WAKABAYASHI H, HASEGAWA M, NISHIOKA Y, MINAMI Y, NISHIOKA K, SUDO A: Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure. Clin Rheumatol 2013; 32: 253-9.
13. BENUCCI M, MANFREDI M, SAVIOLA G, SARZI-PUTTINI P, ATZENI F: Changes in atherosclerosis markers during tocilizumab treatment in rheumatoid arthritis: preliminary results. Clin Exp Rheumatol 2013; 31: 322-3.
14. HAN C, SMOLEN J, KAVANAUGH A et al.: Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis. Arthritis Care Res 2008; 59: 510-4.
15. YAZICI Y, MONIZ REED D, KLEM C, ROSENBLATT L, WU G, KREMER JM: Greater remission rates in patients withn early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept:a post hoc analysis of randomised clinical trial data. Clin Exp Rheumatol 2011; 29: 494-9.
16. BRUNS A, NICAISE-ROLAND P, HAYEM G et al.: Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Joint Bone Spine 2009; 76: 248-53.
17. FREESTON JE, CONAGHAN PG, DASS S et al.: Does extremity-MRI improve erosion detection in severely damaged joints? A study of long-standing rheumatoid arthritis using three imaging modalities. Ann Rheum Dis 2007; 66: 1538-40.
18. MITTENDORF T, DIETZ B, STERZ R et al.: Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective. Rheumatology 2008; 47: 188-93.
19. FURNERI G, MANTOVANI LG, BELISARI A et al.: Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 2012; 30 (Suppl. 73): S72-84.
20. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
21. SINGH JA, FURST DE, BHARAT A et al.: 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012; 64: 625-39.
22. KARONITSCH T, ALETAHA D, BOERS M et al.: Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1365-73.
23. FELSON D: Defining remission in rheumatoid arthrit. Ann Rheum Dis 2012; 71 (Suppl. 2): i86-8
24. MANEIRO RJ, SALGADO E, CARMONA L, GOMEZ-REINO JJ: Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. Semin Arthritis Rheum 2013; 43: 9-17.